Jul. 21 at 5:34 PM
$NSPR Investors and analysts want to see raw numbers. Just wait for Q3 earnings to show revenues increasing tenfold. Even Q2 earnings can show a big jump if they had shipments standing by for those final 2 weeks of the quarter when CGuard Prime got BOTH FDA approval and CE mark. I am incredibly hopeful that the carotid artery stenting world turns to CGuard for all future procedures. I mean - why would any doctor put an inferior stent into a patient?
To further capitalize on the market, as revenues increase from 2025 to 2026, NSPR will soon get TCAR approval for CGuard Prime, in addition to the one of few peripherals to even conduct the procedure with SwitchGuard.
What I think we have is a massive snowball slowly building up. I know FDA approval did not give returns, but that is also a speculative event. What is not speculative is when NSPR puts words into actions.
